Published Online
on
April 15, 2002
Circulation. 2002
Published online before print April 15, 2002,
doi: 10.1161/01.CIR.0000015982.70785.B7
A more recent version of this article appeared on April 30, 2002
© American Heart Association, Inc.
Clinical Investigation and Reports |
Phase 1/2 Placebo-Controlled, Double-Blind, Dose-Escalating Trial of Myocardial Vascular Endothelial Growth Factor 2 Gene Transfer by Catheter Delivery in Patients With Chronic Myocardial Ischemia
Douglas W. Losordo, MD*;
Peter R. Vale, MD*;
Robert C. Hendel, MD;
Charles E. Milliken, MS;
F. David Fortuin, MD;
Nancie Cummings, RN;
Richard A. Schatz, MD;
Takayuki Asahara, MD;
Jeffrey M. Isner, MD
Richard E. Kuntz, MD
From the Divisions of Cardiology (D.W.L., P.R.V., N.C., T.A., J.M.I.) and Cardiovascular Research (D.W.L., P.R.V., J.M.I., C.E.M.) Tufts School of Medicine/St Elizabeth’s Medical Center, Boston, Mass; Division of Cardiology, Rush-Presbyterian–St Luke’s Medical Center (R.C.H.), Chicago, Ill; Department of Cardiology, Scripps Clinic (F.D.F., R.A.S.), La Jolla, Calif; Harvard Medical School Division of Biometrics, Brigham and Women’s Hospital (R.E.K.), Boston, Mass.
Correspondence to Douglas W. Losordo, MD, St Elizabeth’s Medical Center, 736 Cambridge St, Boston, MA 02135. E-mail douglas.losordo{at}tufts.edu
 |
Abstract
|
|---|
Background— This phase 1/2 study investigated the safety
of percutaneous catheter-based gene transfer of naked plasmid
DNA encoding for vascular endothelial growth factor 2 (phVEGF2)
to left ventricular (LV) myocardium in a prospective, randomized,
double-blind, placebo-controlled, dose-escalating study of inoperable
patients with class III or IV angina.
Methods and Results— A steerable deflectable 8F catheter with a 27-gauge needle at its distal tip was advanced percutaneously to the endocardial surface of the LV in 19 patients (age, 61±2 years) with chronic myocardial ischemia who were not candidates for conventional revascularization. Patients were randomized in a double-blind fashion to receive 6 injections (total volume, 6.0 mL) of placebo or phVEGF2 in doses of 200 µg (n=9), 800 µg (n=9), or 2000 µg (n=1) guided by LV electromechanical (NOGA) mapping with a gene-to-placebo ratio of 2:1. A total of 114 LV injections were delivered and caused no hemodynamic alterations, sustained ventricular arrhythmias, ECG evidence of infarction, or ventricular perforation. End-point analysis at 12 weeks disclosed a statistically significant improvement in Canadian Cardiovascular Society (CCS) angina class in phVEGF2-treated versus placebo-treated patients (-1.3 versus -0.1, P=0.04). Remaining efficacy end points—including change in exercise duration (91.8 versus 3.9 seconds), functional improvement by 
2 CCS classes (9 of 12 versus 1 of 6), and Seattle Angina Questionnaire data—all showed strong trends favoring efficacy of phVEGF2 versus placebo treatment.
Conclusions— This phase 1/2, double-blind, randomized trial provides preliminary data that support safety of phVEGF2 catheter-mediated myocardial gene transfer. The statistically significant reduction in anginal class and strong positive trends for remaining end points suggest that a larger phase 2/3 trial is warranted.
Key Words: growth substances • gene therapy • ischemia • angina • angiogenesis
|
Introduction
|
|---|
Phase 1/2 human clinical trials of myocardial gene transfer
(GTx) for therapeutic angiogenesis have thus far involved direct
intraoperative injection of plasmid DNA or adenoviral vectors
encoding angiogenic cytokines directly into ischemic myocardium.
1–5 Although these trials demonstrated safety and feasibility in
patients with end-stage coronary artery disease, the use of
operative thoracotomy precluded randomization against placebo.
Nevertheless, objective evidence of improvement in myocardial
perfusion after GTx was demonstrated by both single-photon emission
CT (SPECT) radionuclide perfusion imaging and left ventricular
(LV) electromechanical (NOGA) mapping (EMM).
4 Although mini-thoracotomy
proved to be generally well tolerated, the risks of general
anesthesia and manipulation of preexisting bypass grafts, particularly
the left internal mammary artery, limit its initial and repeat
applications.
Nonoperative myocardial GTx in human subjects was initiated as catheter-based intracoronary infusion of viral vectors encoding for angiogenic growth factors.6 This method, however, is not effective for so-called naked plasmid DNA (DNA delivered without the use of viral vectors) because plasmid DNA is rapidly degraded in circulating blood. Accordingly, preclinical studies7,8 demonstrated that intramyocardial injections of plasmid DNA by a novel delivery catheter in conjunction with LV (NOGA) EMM could be used to safely perform percutaneous myocardial GTx to porcine myocardium. A human pilot study in 6 subjects with refractory myocardial ischemia has subsequently provided early feasibility and safety data for percutaneous myocardial GTX of naked plasmid DNA encoding vascular endothelial growth factor-2 (phVEGF2) to human LV myocardium.9
In the present report, we describe the results of a randomized, double-blind, placebo-controlled, dose-escalating clinical designed to further investigate the safety of percutaneous catheter-based GTx of naked plasmid DNA encoding for phVEGF2 into the LV myocardium of patients with class III or IV angina.
|
Methods
|
|---|
Patients
Eligibility for catheter-based myocardial GTx included Canadian
Cardiovascular Society (CCS) class III or IV angina refractory
to maximum medical therapy, multivessel coronary artery disease
not suitable for bypass surgery or angioplasty, and reversible
ischemia on stress SPECT Tc 99m sestamibi nuclear imaging. Subjects
were excluded if they had a previous history or current evidence
of malignancy, active diabetic retinopathy, or evidence of severe
LV systolic dysfunction (LV ejection fraction [EF] <20% by
transthoracic 2D echocardiography). All patients were managed
on their maximized medical therapy as required after GTx.
All protocols were approved by the Institutional Review Board and Institutional Biosafety Committee of St Elizabeth’s Medical Center (Boston, Mass) and Scripps Clinic (La Jolla Calif), as well as by the US Food and Drug Administration (FDA, Center for Biologics Evaluation and Research).
LV Electromechanical Mapping
Subjects underwent nonfluoroscopic LV EMM immediately before GTx to guide injections of naked plasmid VEGF2 DNA to foci of ischemic myocardium. The NOGA system (Biosense, Johnson & Johnson) of catheter-based mapping and navigation has been previously described in detail.7,10–12 Follow-up EMM was performed at 12 weeks after GTx. Editing of the raw data was performed by blinded investigators using the NOGA system and postprocessing analysis package.
SPECT Myocardial Perfusion Study
SPECT Tc 99m sestamibi nuclear perfusion studies were performed in all patients before GTx; in 12 patients, including 7 who received phVEGF2, the study was repeated on day 90 after GTx using the identical stress and rest protocol and sequence as well as the same radiopharmaceutical. The remaining 7 patients did not undergo follow-up Tc 99m sestamibi scans after the protocol had been placed on clinical hold.
The poststress images were acquired 
10 minutes after the conclusion of the dipyridamole infusion. Rest imaging was acquired before the performance of the dipyridamole stress test. The unprocessed image data were submitted to a core laboratory, where the images were reconstructed and reoriented in a uniform fashion in the standard 3 projections (short-axis, vertical, and longitudinal long-axis) for analysis. The SPECT images were then visually interpreted, blinded to clinical data and timing of study, with the use of a semi-quantitative 20-segment model. Perfusion scores (0 to 4, normal to absent activity) were calculated for each patient on the basis of the Cedars-Sinai 20-segment short-axis system.13 Summed stress (SSS) summed rest (SRS) scores were determined by adding all segments scores for the stress and rest studies respectively. The sum difference score reflects the amount of myocardial ischemia and was determined by the subtraction of the SRS from the SSS.
Plasmid DNA
The phVEGF2 plasmid containing the complementary DNA sequence encoding the 52-kDa human VEGF2 (Vascular Genetics Inc) was administered via the injection catheter (vide infra). This expression plasmid is 5283 bp in length and was constructed by Human Genome Sciences. Preparation and purification from cultures of phVEGF2-transformed Escherichia coli were performed by the Puresyn PolyFlo method and contained 1.22 mg/mL plasmid DNA in phosphate-buffered saline (20 mmol/L, pH 7.2, containing 0.01% [w/v] edetate disodium).
Randomization and Dose Allocation
Patients were randomized with a gene-to-placebo ratio of 2:1 (phVEGF2 or saline) in 3 escalating-dose groups: 200, 800, and 2000 µg. The study design prescribed 9 patients for each dose cohort (6 phVEGF2 and 3 placebo patients for each dose) and, thus, 18 phVEGF2 versus 9 placebo subjects by study completion.
Percutaneous Catheter-Based Myocardial Injection
After completion of LV EMM, the mapping catheter was replaced by the injection catheter (Biosense-Webster), a modified 8F mapping catheter, the distal tip of which incorporates a 27-gauge needle, that can be advanced or retracted by 4 to 6 mm. The catheter was flushed with sterile saline for 30 to 45 minutes before injections, thus prefilling the lumen before introduction of the catheter into the circulation. The injection catheter was then advanced retrograde via an 8F femoral arterial introducer sheath, across the aortic valve into the LV, and manipulated to acquire stable points based on the parameters described above within the target region that had been superimposed on the previously acquired 3D map.
Once a stable NOGA point was attained, the needle was advanced 4 to 6 mm into the myocardium; myocardial penetration was confirmed by transient myocardial injury by the intracardiac electrogram recorded from the catheter tip and/or premature ventricular contractions at the time of needle advancement. In each patient, a total of 6 injections were performed into foci of myocardial ischemia identified as areas of preserved unipolar voltage and abnormal wall motion via EMM (NOGA) mapping. Each injection consisted of 1 mL of solution (total volume, 6 mL/patient), delivered from a 1-mL syringe, of placebo (saline) or phVEGF2 in doses of 200, 800, or 2000 µg. After completion of each injection, the needle was retracted, the catheter manipulated to another endocardial site within the zone of ischemia, and a new syringe was used to perform an additional injection. After the final injection and before needle retraction, the lumen was again flushed with 0.1 mL of sterile saline.
Clinical Outcomes
The prespecified primary efficacy parameters were change from baseline in CCS angina classification and exercise tolerance at the 12-week follow-up visit.
All patients were observed for 24 hours after the procedure in the coronary care unit. Serial myocardial isoenzymes (CPK-MB) were measured for the first 24 hours. Serial ECGs and standard transthoracic echocardiograms were performed preoperatively, within 24 hours after the procedure, and at each follow-up visit (weeks 2, 4, 8, 12).
At each postoperative visit, Seattle Angina Questionnaires were completed, weekly number of angina episodes and nitroglycerin consumption was documented, and functional assessment based on CCS classification14 was performed by investigators blinded to treatment assignment. Patients were also evaluated specifically for evidence of peripheral edema and congestive heart failure. Exercise treadmill testing was performed at baseline and at week 12 using a modified Bruce protocol.15
Major complications were defined as acute myocardial infarction (CPK-MB >2x normal with or without associated electrocardiographic changes), ventricular perforation, sustained ventricular arrhythmias requiring institution of pharmacologic or mechanical therapy, stroke, or death.
Statistical Analysis
This trial was designed as a prospective, double-blind, placebo-controlled dose-escalating trial of 27 patients randomized to either gene or placebo in a 2:1 ratio for each of 3 dose cohorts. The trial was powered to identify a statistically significant increase in CCS functional class. The original design provided a blinded crossover option (to whatever therapy the patient had not received initially) for patients whose clinical status deteriorated or failed to improve after a minimum of 90 days of follow-up. Data are reported as mean±SEM. Comparisons between paired variables were performed using a Student’s t test, with a significance level of P<0.05. Statistical analysis was performed comparing primary efficacy end points between phVEGF2 (n=12) and placebo (n=7) groups from baseline to 12-week follow-up. After 19 subjects had been enrolled (and before any were eligible for crossover), the trial was interrupted by the FDA in the wake of the death of an 18-year-old subject enrolled in an unrelated study of ornithine transcarbamylase deficiency involving adenoviral GTx16; accordingly, doses of phVEGF2 in the current trial were pooled to improve statistical power. Two-tail t tests were performed for continuous data, and count data were computed by exact testing procedures.
|
Results
|
|---|
Patients
Nineteen of the planned 27 patients were enrolled when the study
was interrupted by the FDA. There were 9 patients enrolled in
the 200-µg dose cohort, 9 patients in the 800-µg
cohort, and 1 patient in the 2000-µg group. Demographic
and clinical data for the 19 patients (age, 61±2 years)
are shown in the
Table.
LV Mapping Procedure
Areas of electrically viable myocardium (UpV 5 mV) associated with abnormal/impaired wall motion (linear local shortening <12%), ie, electromechanical uncoupling diagnostic of ischemia by the NOGA (Biosense-Webster) system, were detected in all patients before GTx. Foci of ischemia were identified in all patients and involved the anterior (n=4), anteroseptal (n=1), anterolateral (n=3), lateral (n=5), inferolateral (n=3), posterolateral (n=2), and posterior (n=1) LV walls.
Percutaneous LV GTx
Nineteen patients underwent a total of 114 percutaneous catheter-based myocardial injections, including 12 patients randomized to phVEGF2 GTx and 7 randomized to the placebo injections. Injections were found to cause no significant changes in heart rate or in systolic or diastolic blood pressure. Transient unifocal ventricular ectopic activity was observed at the time of needle extension into the myocardium. In all patients, premature ventricular contractions occurred during injection of the solution of study drug, but no episodes of sustained ventricular arrhythmias were observed. Similarly, no sustained myocardial injury pattern was observed during the injections, as recorded by continuous precordial or endocardial electrograms.
Continuous ECG monitoring was maintained for 24 hours after injection and disclosed no sustained arrhythmias. Subsequent ECGs showed no evidence of postprocedure acute myocardial infarction or recurrent ischemia in any patient. The CPK-MB was not elevated above normal limits in any patient after injection. There were no major complications, including no echocardiographic evidence of pericardial effusion and/or cardiac tamponade.
Clinical Outcomes
The primary efficacy end point for this clinical trial was CCS anginal class status. All patients were classified as CCS class 3 or 4 anginas before randomization. At 12-week follow-up, mean CCS class was decreased (ie, improved) significantly in phVEGF2-transfected patients (pre-GTx 3.5±0.2 versus post-GTx 2.2±0.4, P=0.012) (Figure 1A); 4 of 12 patients improved by 2 classes, 4 of 12 patients improved by 3 classes, and 1 of 12 reported elimination of angina (Figure 1B). In contrast, mean CCS class did not change significantly for placebo patients (preinjection 3.3±0.2 versus postinjection 3.1+0.3; P=0.6), whereas 1 of 7 reported elimination of angina; none of the remaining 6 placebo patients improved by >1 functional class. Comparison of functional class at 12 weeks disclosed a statistically significant mean change in CCS angina class for phVEGF2 compared with placebo (-1.3 versus 0.1, P=0.04) (Figure 1C).
View larger version (29K):
[in this window]
[in a new window]
|
Figure 1. Anginal classification before and 12 weeks after treatment. A, At 12-week follow-up, mean CCS functional class was decreased (ie, improved) significantly in phVEGF2-transfected patients (pre-GTx 3.5±0.2 versus post-GTx 2.2±0.4, P=0.012) but did not change significantly for placebo patients (3.3±0.2 preinjection versus 3.1+0.3 postinjection, P=0.6). B, Among 12 patients transfected with phVEGF2, 4 improved by 2 classes, 4 improved by 3 classes, and 1 reported elimination of angina. In contrast, although 1 of 7 placebo patients reported elimination of angina, none of the remaining 6 placebo patients improved by >1 functional class. C, Comparison of functional class at 12 weeks disclosed a statistically significant mean change in CCS angina class for phVEGF2 compared with placebo (-1.3 versus 0.1, P=0.04). D, Seattle Angina Questionnaire end points showed trends favoring efficacy of phVEGF2 versus placebo treatment, although these findings did not reach statistical significance.
|
|
Clinically, phVEGF2-transfected patients reported a reduction in anginal episodes per week (23.7±4.9 versus 10.3±5.7, P=0.04). In contrast, the reduction reported in placebo patients was not significant (20.4±4.7 versus12.1±6.3, P=0.32). Weekly consumption of nitroglycerin tablets was reduced in both groups at 12 weeks post-GTx, but failed to achieve statistical significance (16.6±5.4 versus 8.8±5.8, P=0.26, for phVEGF2-transfected patients; 18.1±6.4 versus 9.9±6.6, P=0.35, for placebo patients). Seattle Angina Questionnaire end points showed trends favoring efficacy of phVEGF2 versus placebo treatment (Figure 1D), although these findings did not reach statistical significance.
Comparison of clinical end points between phVEGF2-transfected patients (dose 200 µg, n=6; dose 800 µg, n=6) disclosed no significant differences for functional class (P=0.71), weekly angina episodes (P=0.41), or nitrate tablets consumption (P=0.26).
LVEF, determined by transthoracic 2D echocardiography, was not significantly altered at week 12 follow-up. For phVEGF2-transfected patients, LVEF before GTx was 49.9±14% versus 48.6±12% for after GTx (mean±SD, P=NS); for control patients, mean LVEF before and after injection was 50.4±13% versus 54±13% (P=NS).
Exercise Treadmill Testing
Modified Bruce protocol exercise tolerance testing was performed in all patients. The mean duration of exercise increased significantly at 12-week follow-up in phVEGF2-transfected patients (479.0±51.5 versus 607.3±52.4 seconds, P=0.02) but was unchanged in patients randomized to placebo (426.4±103.4 versus 432.0±116.3 seconds, P=0.92) (Figure 2A). The mean increase in exercise duration for the phVEGF2 cohort after randomization (91.8 seconds) was nearly 1.5 minutes greater than that of the placebo group (3.9 seconds, P=0.26 for comparison of active versus placebo, Figure 2B).
View larger version (14K):
[in this window]
[in a new window]
|
Figure 2. Exercise tolerance before and 12 weeks after treatment. A, The mean duration of exercise increased significantly at 12-week follow-up in phVEGF2-transfected patients (479.0±51.5 versus 607.3±52.4 seconds, P=0.02) but was unchanged in patients randomized to placebo (426.4±103.4 versus 432.0±116.3 seconds, P=0.92). B, The mean increase in exercise duration for the phVEGF2 cohort after randomization (91.8 seconds) was nearly 1.5 minutes greater than that of the placebo group (3.9 seconds, P=0.26 for comparison of active versus placebo).
|
|
Electromechanical Mapping
LV EMM (Figures 3 and 4) was available for analysis in 15 patients. Mean unipolar and bipolar voltage recordings 5 mV and 2 mV, respectively, defining myocardial viability in the ischemic segments, did not change significantly after GTx. Mean LLS in segments of myocardial ischemia, however, improved significantly from 5.9±1.0% to 13.2±1.3% (P=0.004) in patients transfected with phVEGF2. The area of ischemic myocardium was consequently reduced from 6.4±2.2 (before GTx) to 2.6±1.4cm2 (after GTx) (P=0.013) in these patients.
View larger version (31K):
[in this window]
[in a new window]
|
Figure 3. SPECT and NOGA findings in phVEGF2-transfected patient. A, SPECT Tc 99m sestamibi nuclear perfusion study shows anterolateral perfusion defects at rest (red arrow) and with pharmacological stress (yellow arrow) before GTx (pre-GT). After GTx (post-GT), anterolateral resting defect has resolved, whereas stress-associated defect is improved. B, NOGA maps in same patient confirm the anterolateral ischemic region pre-GT (red zone in top right), which is nearly resolved post-GT (bottom right).
|
|
View larger version (34K):
[in this window]
[in a new window]
|
Figure 4. SPECT and NOGA findings in placebo-transfected patient. This patient reported elimination of angina at 12 weeks. A, Perfusion defect seen on resting SPECT Tc 99m sestamibi nuclear perfusion study is enhanced with pharmacological stress (yellow arrow) before GTx. Rest and stress images recorded after GTx are essentially unchanged. B, NOGA maps in same patient confirm essentially no change in anterolateral ischemic region (red zone in top and bottom right) before versus after GTx.
|
|
In contrast, patients in the control group demonstrated no change in the area of ischemia at 90 days after control assignment (5.7±2.1 cm2 preinjection versus 5.4±1.8 cm2 postcontrol, P=0.39), nor was the mean LLS significantly different (ie, LLS remained in the ischemic range) after saline injections (7.5±0.7 [preinjection] to 10.2±1.1% [postinjection], P=0.11).
SPECT Myocardial Perfusion Study
SPECT myocardial perfusion imaging data at baseline and follow-up (Figures 3 and 4) were available for 11 patients, including 7 who received phVEGF2; the remaining patients did not undergo follow-up SPECT scans after the protocol had been placed on clinical hold. Of the 7 patients who received phVEGF2, 5 showed improvement in SSS and 1 showed no change. A trend for improvement (decrease) in SSS was observed after GTx (baseline 11.4±6.2 versus 4 weeks 8.8±5.0, P=0.074), representing a 23% improvement in perfusion score. A similar trend was noted in the summed difference score (baseline 6.8±5.1 versus 4 weeks 4.0±1.5, P=0.118), constituting a 42% improvement owing to improvement observed in 5 of 7 patients who received phVEGF2. The placebo patients demonstrated a nonsignificant increase in the SSS, with only 1 patient demonstrating a decrease in the score. Similar findings were apparent for the placebo group when examining the summed difference score. An analysis confined to only those segments that were abnormally perfused at baseline demonstrated a significant improvement in the SSS for the GTx patients (baseline 1.65±0.44 versus 4 weeks 1.07±0.50, P=0.016); no change was noted for the placebo group.
Complications
There were no acute complications from any of the 114 catheter injections performed in this study. During the follow-up period after GTx, 1 patient who had received a placebo injection suffered a cerebrovascular accident and myocardial infarction 4 weeks after procedure. A second patient who received placebo experienced worsening of his anginal symptoms. Although the approved FDA Investigational New Drug application provided crossover to active treatment in the event of clinical deterioration, this option was precluded by the clinical hold and permission for compassionate use could not be obtained; this patient consequently underwent percutaneous transluminal coronary angioplasty and stent treatment of a saphenous vein bypass graft to the right coronary artery with no subsequent change in his functional (CCS 3) status. A third placebo patient experienced a transient (cerebrovascular) ischemic attack 3 weeks after the procedure.
Among patients who received phVEGF2, 1 patient with a history of mild aortic stenosis, heart failure, and sleep apnea failed to improve after 800 µg phVEGF2; this patient ultimately underwent PTCA at another institution without success 1 year after GTx and was subsequently hospitalized on multiple occasions for unstable angina and pneumonia complicated by myocardial infarction. A second patient with underlying heart failure and an LVEF of 25% initially experienced improvement in his anginal symptoms after 200 µg phVEGF2 GTx, including an increase in exercise treadmill time from 3:54 to 5:27 minutes. Progression of the patient’s heart failure, however, led to cardiac transplantation 9 months after GTx.
|
Discussion
|
|---|
This randomized, double-blind, placebo-controlled, dose-escalating
clinical trial was designed to further investigate the safety
of percutaneous catheter-based GTx of naked plasmid DNA encoding
for phVEGF2 into the LV myocardium of patients with class III
or IV angina. A total of 114 LV injections were delivered and
caused no hemodynamic alterations, sustained ventricular arrhythmias,
ECG evidence of infarction, or ventricular perforation. Comparison
of efficacy end points at 12 weeks disclosed a statistically
significant change in CCS angina class, which decreased by 1.3
in phVEGF2-treated patients versus 0.1 in placebo-treated patients
(
P=0.04). Remaining efficacy end points—including change
in exercise duration (91.8 versus 3.9 seconds), functional improvement
by
2 CCS classes (9 of 12 versus 1 of 7), and Seattle Angina
Questionnaire data—all showed strong trends favoring efficacy
of phVEGF2 versus placebo treatment.
Intramyocardial injection is required in the case of naked plasmid DNA, because the plasmid would undergo prompt degradation were it to be delivered into circulating blood. This is in direct contrast to viral vectors, which are not subject to similar intravascular degradation and may thus be delivered via an intracoronary route.6 The strategy of direct intramyocardial injection is designed to shield naked DNA for effective GTx and to avoid potential toxicities that might result from the use of viral vectors. Moreover, because there is a lower risk of provoking an immune response to naked DNA than a viral vector, the combined use of naked DNA and catheter delivery preserves the option for repetitive administration, should that be proven effective. Although naked DNA GTx is less efficient than viral GTx, previous work has demonstrated that genes encoding proteins that are naturally secreted from intact cells, such as VEGF, can achieve meaningful biological outcomes despite low transfection efficiency.17,18 Our positive experience in the present study with 144 injections in 19 patients adds to previously reported positive experience involving 36 injections performed with the same catheter system in 6 patients9 and in other preclinical studies.7,8 The cumulative absence of any acute adverse events with this catheter system is encouraging for percutaneous myocardial injection as a safe vehicle for myocardial GTx.
Previous reports of subjective and objective improvement after VEGF GTx have been limited to dose-escalating trials involving consecutive-treated, nonrandomized patients with critical limb19,20 or myocardial1–4 ischemia. In each of these studies, interpretation of symptomatic outcome in particular was complicated by the lack of a placebo-treated control group. Inclusion of a control group was recently facilitated by the advent of catheter-based GTx, which minimized the ethical dilemma of blinded placebo controls,7,8,12 whereas a previous 6-patient pilot trial using this approach showed reduction in anginal symptoms and nitroglycerin use in VEGF2 versus placebo patients. This trial was limited because it was a single-blind design in which patients randomized to the control arm underwent a mock procedure (the catheter was advanced to the LV, but no injection was performed).
In this regard, the current double-blind, placebo-controlled results are encouraging and consistent with the previous nonrandomized or single-blind results of myocardial GTx. Despite the small size of the patient cohort, it was nevertheless possible to demonstrate a statistically significant improvement in CCS anginal classification. Although the size of this initial cohort did not permit the changes observed in exercise testing to reach statistical significance, the increase in treadmill time after VEGF2 GTx (91.8 seconds) far exceeded that observed for control subjects (3.9 seconds) and was similar to or in excess of what has been previously described for patients receiving laser myocardial revascularization or continued medical therapy in 5 contemporary controlled studies.21–25
The possibility that improvement in symptomatic status documented in the current and previous trials of myocardial VEGF2 GTx constitutes evidence of bioactivity is further supported by objective evidence in these trials of enhanced myocardial perfusion. In patients undergoing intraoperative, direct myocardial injection of VEGF naked DNA, for example, stress SPECT Tc 99m sestamibi myocardial imaging disclosed that mean perfusion-defect scores for both stress and rest images were significantly decreased (ie, improved) at day 60. It is particularly intriguing to note that not only defects observed in the perfusion scans with pharmacologic stress, but also those observed at rest, improved after GTx. This observation suggests that these pretest defects constitute foci of hibernating myocardium rather than myocardial scar26–28 and may have been successfully resuscitated as the result of therapeutic neovascularization.
Rescue of foci of hibernating myocardium after VEGF GTx was subsequently confirmed in a subset of 13 consecutive patients by the use of catheter-based EMM,4 shown to distinguish among infarcted, ischemic, and normal myocardium.12,29 Moreover, the identical LV anatomic site that was observed to be improved by EMM was consistently observed to be improved by SPECT Tc 99m sestamibi myocardial perfusion imaging as well. Initial experience with catheter-based GTx in the single-blind study referred to above confirmed these findings by demonstrating reproducibility of the SPECT and EMM maps from baseline to post-mock procedure, followed by site-specific improvement in both SPECT and EMM 90 days after the patient crossed over to VEGF2 GTx. The SPECT and EMM findings showing evidence of improved perfusion in the current trial are thus consistent with these previous studies of VEGF GTx.
This preliminary experience suggests that it is feasible to replace currently employed operative approaches with minimally invasive techniques for applications of cardiovascular gene therapy designed to target myocardial function and perfusion. Such an approach may have at least 3 advantages compared with those of an operative approach. First, it potentially allows more selective delivery of the transgene to targeted ischemic zones, including sites that are less accessible by a mini-thoracotomy. Second, the catheter-based approach, because it obviates the need for general anesthesia and operative dissection through adhesions related to placement of previous bypass conduits, facilitates placebo-controlled, double-blind testing of myocardial GTx. Third, the intervention can be performed as an outpatient procedure and repeated if necessary. These findings thus indicate that further similarly designed studies to establish definitive evidence of safety and efficacy of the approach used here in a larger patient cohort are merited.
|
Acknowledgments
|
|---|
Dr Vale is the recipient of a fellowship from Bracco Diagnostics
Inc/Society for Cardiac Angiography and Interventions. Additional
support for this trial was provided by grants from the E.L.
Weigand Foundation (Reno, NV) and the Peter Lewis Educational
Foundation, (Cleveland, Ohio). Dr Isner is a cofounder of Vascular
Genetics Inc (VGI). Drs Isner and Schatz are stockholders in
VGI, which cosponsored this trial with Biosense-Webster. None
of the authors has any financial relationship with Biosense-Webster.
The contributions of the late Thomas Precopio of Biosense Webster
to this project are acknowledged and remembered with appreciation
and respect.
|
Footnotes
|
|---|
*Drs Losordo and Vale contributed equally to this work.
Received December 21, 2001;
accepted March 8, 2002.
|
References
|
|---|
1.
Losordo DW, Vale PR, Symes J, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF
165 as sole therapy for myocardial ischemia.
Circulation. 1998; 98: 2800–2804.
[Abstract/Full Text]
2.
Symes JF, Losordo DW, Vale PR, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: preliminary clinical results. Ann Thorac Surg. 1999; 68: 830–837.[Abstract/Full Text]
3.
Rosengart TK, Lee LY, Patel SR, et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration and adenovirus vector expressing the VEGF121 cDNA. Ann Surg. 1999; 230: 466–472.[Medline]
4.
Vale PR, Losordo DW, Milliken CE, et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF165 gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation. 2000; 102: 965–974.[Abstract/Full Text]
5.
Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expression VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999; 100: 468–474.[Abstract/Full Text]
6.
Giordano FJ, Ping P, McKirnan D, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nature Med. 1996; 2: 534–539.[Medline]
7.
Vale PR, Losordo DW, Tkebuchava T, et al. Catheter-based myocardial gene transfer utilizing nonfluoroscopic electromechanical left ventricular mapping. J Am Coll Cardiol. 1999; 34: 246–254.[Medline]
8.
Kornowski R, Leon MB, Fuchs S, et al. Electromagnetic guidance for catheter-based transendocardial injection: a platform for intramyocardial angiogenesis therapy. J Am Coll Cardiol. 2000; 35: 1031–1039.[Medline]
9.
Vale PR, Losordo DW, Milliken CE, et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation. 2001; 103: 2138–2143.[Abstract/Full Text]
10.
Ben-Haim SA, Osadchy D, Schuster I, et al. Nonfluoroscopic, in vivo navigation and mapping technology. Nature Med. 1996; 2: 1393–1395.[Medline]
11.
Gepstein L, Hayam G, Ben-Haim SA. A novel method for nonfluoroscopic catheter-based electroanatomical mapping of the heart: in vitro and in vivo accuracy results. Circulation. 1997; 95: 1611–1622.[Abstract/Full Text]
12.
Kornowski R, Hong MK, Gepstein L, et al. Preliminary animal and clinical experiences using an electromechanical endocardial mapping procedure to distinguish infarcted from healthy myocardium. Circulation. 1998; 98: 1116–1124.[Abstract/Full Text]
13.
Germano G, Erel J, Lewin H, et al. Automatic quantitation of regional myocardial wall motion and thickening from gated technetium-99 m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol. 1997; 30: 1360–1367.[Medline]
14.
Campeau L. Grading of angina pectoris. Circulation. 1976; 54: 522–523. Letter.
15.
McInnis KJ, Balady GJ, Weiner DA, et al. Comparison of ischemic and physiologic responses during exercise tests in men using the standard and modified Bruce protocols. Am J Cardiol. 1992; 69: 84–89.[Medline]
16.
Lehrman S. Virus treatment questioned after gene therapy death. Nature. 1999; 401: 517.[Medline]
17.
Losordo DW, Pickering JG, Takeshita S, et al. Use of the rabbit ear artery to serially assess foreign protein secretion after site specific arterial gene transfer in vivo: evidence that anatomic identification of successful gene transfer may underestimate the potential magnitude of transgene expression. Circulation. 1994; 89: 785–792.[Abstract]
18.
Takeshita S, Losordo DW, Kearney M, et al. Time course of recombinant protein secretion following liposome-mediated gene transfer in a rabbit arterial organ culture model. Lab Invest. 1994; 71: 387–391.[Abstract]
19.
Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 following intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998; 97: 1114–1123.[Abstract/Full Text]
20.
Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis obliterans (Buerger’s disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg. 1998; 28: 964–975.[Medline]
21.
Schofield PM, Sharples LD, Caine N, et al. Transmyocardial laser revascularisation in patients with refractory angina: a randomised controlled trial. Lancet. 1999; 353: 519–524.[Medline]
22.
Burkhoff D, Schmidt S, Schulman SP, et al. Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomised trial. Lancet. 1999; 354: 885–890.[Medline]
23.
Allen KB, Dowling RD, Fudge TL, et al. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. N Engl J Med. 1999; 341: 1029–1036.[Abstract/Full Text]
24.
Frazier OH, March RJ, Horvath KA, et al. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med. 1999; 341: 1021–1028.[Abstract/Full Text]
25.
Aaberge L, Nordstrand K, Dragsund M, et al. Transmyocardial revascularization with CO2 laser in patients with refractory angina pectoris: clinical results from the Norwegian randomized trial. J Am Coll Cardiol. 2000; 35: 1170–1177.[Medline]
26.
Shen Y-T, Vatner SF. Mechanism of impaired myocardial function during progressive coronary stenosis in conscious pigs: hibernation versus stunning? Circ Res. 1995; 76: 479–488.[Abstract/Full Text]
27.
Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med. 1998; 3: 173–181.
28.
Dilsizian V, Bonow RO. Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium. Circulation. 1993; 87: 1–20.[Medline]
29.
Gepstein L, Goldin A, Lessick J, et al. Electromechanical characterization of chronic myocardial infarction in the canine coronary occlusion model. Circulation. 1998; 98: 2055–2064.[Abstract/Full Text]
This article has been cited by other articles:
|
|
|
|
 
W. Schgoer, M. Theurl, J. Jeschke, A. G.E. Beer, K. Albrecht, R. Gander, S. Rong, D. Vasiljevic, M. Egger, A. M. Wolf, et al.
Gene Therapy With the Angiogenic Cytokine Secretoneurin Induces Therapeutic Angiogenesis by a Nitric Oxide-Dependent Mechanism
Circ. Res.,
November 6, 2009;
105(10):
994 - 1002.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Gupta, J. Tongers, and D. W. Losordo
Human Studies of Angiogenic Gene Therapy
Circ. Res.,
October 9, 2009;
105(8):
724 - 736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Zhang, L. Ding, Y. Zhao, W. Sun, B. Chen, H. Lin, X. Wang, L. Zhang, B. Xu, and J. Dai
Collagen-Targeting Vascular Endothelial Growth Factor Improves Cardiac Performance After Myocardial Infarction
Circulation,
April 7, 2009;
119(13):
1776 - 1784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Lavine and D. M. Ornitz
Shared Circuitry: Developmental Signaling Cascades Regulate Both Embryonic and Adult Coronary Vasculature
Circ. Res.,
January 30, 2009;
104(2):
159 - 169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Birk, J. Barbato, L. Mureebe, and R. A. Chaer
Basic Science Review: Current Insights on the Biology and Clinical Aspects of VEGF Regulation
Vascular and Endovascular Surgery,
January 1, 2009;
42(6):
517 - 530.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Saeed, A. Martin, A. Jacquier, M. Bucknor, D. Saloner, L. Do, P. Ursell, H. Su, Y. W. Kan, and C. B. Higgins
Permanent Coronary Artery Occlusion: Cardiovascular MR Imaging Is Platform for Percutaneous Transendocardial Delivery and Assessment of Gene Therapy in Canine Model
Radiology,
November 1, 2008;
249(2):
560 - 571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Baldazzi, E. Jorgensen, R. S. Ripa, and J. Kastrup
Release of biomarkers of myocardial damage after direct intramyocardial injection of genes and stem cells via the percutaneous transluminal route
Eur. Heart J.,
August 1, 2008;
29(15):
1819 - 1826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Sinusas
Targeted imaging offers advantages over physiological imaging for evaluation of angiogenic therapy.
J. Am. Coll. Cardiol. Img.,
July 1, 2008;
1(4):
511 - 514.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kinnaird, E. Stabile, S. Zbinden, M.-S. Burnett, and S. E. Epstein
Cardiovascular risk factors impair native collateral development and may impair efficacy of therapeutic interventions
Cardiovasc Res,
May 1, 2008;
78(2):
257 - 264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Hobo, T. Shimizu, H. Sekine, T. Shin'oka, T. Okano, and H. Kurosawa
Therapeutic Angiogenesis Using Tissue Engineered Human Smooth Muscle Cell Sheets
Arterioscler Thromb Vasc Biol,
April 1, 2008;
28(4):
637 - 643.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. L. Johnson, L. Schofield, T. Donahay, M. Bouchard, A. Poppas, and R. Haubner
Radiolabeled RGD Peptides to Image Angiogenesis in Swine Model of Hibernating Myocardium.
J. Am. Coll. Cardiol. Img.,
January 1, 2008;
1:
500 - 510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A R Lyon, M Sato, R J Hajjar, R J Samulski, and S E Harding
Gene therapy: targeting the myocardium
Heart,
January 1, 2008;
94(1):
89 - 99.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Horvath and Y. Zhou
Transmyocardial Laser Revascularization and Extravascular Angiogenetic Techniques to Increase Myocardial Blood Flow
Card. Surg. Adult,
January 1, 2008;
3(2008):
733 - 752.
[Full Text]
|
|
|
|
|
|
|
K. Egashira, K. Nakano, K. Ohtani, K. Funakoshi, G. Zhao, Y. Ihara, J.-i. Koga, S. Kimura, R. Tominaga, and K. Sunagawa
Local Delivery of Anti-Monocyte Chemoattractant Protein-1 by Gene-Eluting Stents Attenuates In-Stent Stenosis in Rabbits and Monkeys
Arterioscler Thromb Vasc Biol,
December 1, 2007;
27(12):
2563 - 2568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Iwasaki, K. Fukushima, A. Kawamoto, K. Umetani, A. Oyamada, S. Hayashi, T. Matsumoto, M. Ishikawa, T. Shibata, H. Nishimura, et al.
Synchrotron Radiation Coronary Microangiography for Morphometric and Physiological Evaluation of Myocardial Neovascularization Induced by Endothelial Progenitor Cell Transplantation
Arterioscler Thromb Vasc Biol,
June 1, 2007;
27(6):
1326 - 1333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Saeed, D. Saloner, A. Martin, L. Do, O. Weber, P. C. Ursell, A. Jacquier, R. Lee, and C. B. Higgins
Adeno-associated Viral Vector-Encoding Vascular Endothelial Growth Factor Gene: Effect on Cardiovascular MR Perfusion and Infarct Resorption Measurements in Swine
Radiology,
May 1, 2007;
243(2):
451 - 460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yla-Herttuala, T. T. Rissanen, I. Vajanto, and J. Hartikainen
Vascular Endothelial Growth Factors: Biology and Current Status of Clinical Applications in Cardiovascular Medicine
J. Am. Coll. Cardiol.,
March 13, 2007;
49(10):
1015 - 1026.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. J. Muller, H. A. Katus, and R. Bekeredjian
Targeting the heart with gene therapy-optimized gene delivery methods
Cardiovasc Res,
February 1, 2007;
73(3):
453 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. de Silva, L. F. Gutierrez, A. N. Raval, E. R. McVeigh, C. Ozturk, and R. J. Lederman
X-Ray Fused With Magnetic Resonance Imaging (XFM) to Target Endomyocardial Injections: Validation in a Swine Model of Myocardial Infarction
Circulation,
November 28, 2006;
114(22):
2342 - 2350.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-L. Ang, L. Takura Shenje, L. Srinivasan, and M. Galinanes
Repair of the damaged heart by bone marrow cells: from experimental evidence to clinical hope.
Ann. Thorac. Surg.,
October 1, 2006;
82(4):
1549 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. W. Zhuang, L. Gao, M. Murakami, J. D. Pearlman, T. J. Sackett, M. Simons, and E. D. de Muinck
Arteriogenesis: Noninvasive Quantification with Multi-Detector Row CT Angiography and Three-dimensional Volume Rendering in Rodents
Radiology,
September 1, 2006;
240(3):
698 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ishikawa, M. Eguchi, M. Wada, Y. Iwami, K. Tono, H. Iwaguro, H. Masuda, T. Tamaki, and T. Asahara
Establishment of a Functionally Active Collagen-Binding Vascular Endothelial Growth Factor Fusion Protein In Situ
Arterioscler Thromb Vasc Biol,
September 1, 2006;
26(9):
1998 - 2004.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Wilson, M. Ii, K. W. Park, A. Suli, L. K. Sorensen, F. Larrieu-Lahargue, L. D. Urness, W. Suh, J. Asai, G. A.H. Kock, et al.
Netrins Promote Developmental and Therapeutic Angiogenesis
Science,
August 4, 2006;
313(5787):
640 - 644.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Ripa, Y. Wang, E. Jorgensen, H. E. Johnsen, B. Hesse, and J. Kastrup
Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease
Eur. Heart J.,
August 1, 2006;
27(15):
1785 - 1792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Lavine, A. C. White, C. Park, C. S. Smith, K. Choi, F. Long, C.-c. Hui, and D. M. Ornitz
Fibroblast growth factor signals regulate a wave of Hedgehog activation that is essential for coronary vascular development.
Genes & Dev.,
June 15, 2006;
20(12):
1651 - 1666.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. W. Sellke, R. Laham, E. J. Suuronen, and M. Ruel
Angiogenesis for the treatment of inoperable coronary disease: the future.
Seminars in Cardiothoracic and Vascular Anesthesia,
June 1, 2006;
10(2):
184 - 188.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y Wang, H E Johnsen, S Mortensen, L Bindslev, R Sejersten Ripa, M Haack-Sorensen, E Jorgensen, W Fang, and J Kastrup
Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention
Heart,
June 1, 2006;
92(6):
768 - 774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Nordlie, L. E. Wold, B. Z. Simkhovich, C. Sesti, and R. A. Kloner
Molecular Aspects of Ischemic Heart Disease: Ischemia/Reperfusion-Induced Genetic Changes and Potential Applications of Gene and RNA Interference Therapy
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2006;
11(1):
17 - 30.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y. Tsutsumi and D. W. Losordo
Double Face of VEGF
Circulation,
August 30, 2005;
112(9):
1248 - 1250.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gyongyosi, A. Khorsand, S. Zamini, W. Sperker, C. Strehblow, J. Kastrup, E. Jorgensen, B. Hesse, K. Tagil, H. E. Botker, et al.
NOGA-Guided Analysis of Regional Myocardial Perfusion Abnormalities Treated With Intramyocardial Injections of Plasmid Encoding Vascular Endothelial Growth Factor A-165 in Patients With Chronic Myocardial Ischemia: Subanalysis of the EUROINJECT-ONE Multicenter Double-Blind Randomized Study
Circulation,
August 30, 2005;
112(9_suppl):
I-157 - I-165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ohtsuka, K. Inoue, Y. Hara, N. Morioka, K. Ohshima, J. Suzuki, A. Ogimoto, Y. Shigematsu, and J. Higaki
Serum markers of angiogenesis and myocardial ultrasonic tissue characterization in patients with dilated cardiomyopathy
Eur J Heart Fail,
June 1, 2005;
7(4):
689 - 695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kastrup, E. Jorgensen, A. Ruck, K. Tagil, D. Glogar, W. Ruzyllo, H. E. Botker, D. Dudek, V. Drvota, B. Hesse, et al.
Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: A randomized double-blind placebo-controlled study: The Euroinject One trial
J. Am. Coll. Cardiol.,
April 5, 2005;
45(7):
982 - 988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J Teng, K. Lachapelle, and R. C. Chiu
Reappraisal of Recent Clinical Trials of Angiogenic Therapy in Myocardial Ischemia
Asian Cardiovasc Thorac Ann,
March 1, 2005;
13(1):
90 - 97.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R Corti, J Badimon, G Mizsei, F Macaluso, M Lee, P Licato, J F Viles-Gonzalez, V Fuster, and W Sherman
Real time magnetic resonance guided endomyocardial local delivery
Heart,
March 1, 2005;
91(3):
348 - 353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Davani, F. Deschaseaux, D. Chalmers, P. Tiberghien, and J.-P. Kantelip
Can stem cells mend a broken heart?
Cardiovasc Res,
February 1, 2005;
65(2):
305 - 316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Simoes, M. Miyagawa, S. Reder, C. Stadele, R. Haubner, W. Linke, T. Lehner, P. Epple, M. Anton, M. Schwaiger, et al.
Myocardial Kinetics of Reporter Probe 124I-FIAU in Isolated Perfused Rat Hearts After In Vivo Adenoviral Transfer of Herpes Simplex Virus Type 1 Thymidine Kinase Reporter Gene
J. Nucl. Med.,
January 1, 2005;
46(1):
98 - 105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ohtani, K. Egashira, K.-i. Hiasa, Q. Zhao, S. Kitamoto, M. Ishibashi, M. Usui, S. Inoue, Y. Yonemitsu, K. Sueishi, et al.
Blockade of Vascular Endothelial Growth Factor Suppresses Experimental Restenosis After Intraluminal Injury by Inhibiting Recruitment of Monocyte Lineage Cells
Circulation,
October 19, 2004;
110(16):
2444 - 2452.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kawamoto, T. Murayama, K. Kusano, M. Ii, T. Tkebuchava, S. Shintani, A. Iwakura, I. Johnson, P. von Samson, A. Hanley, et al.
Synergistic Effect of Bone Marrow Mobilization and Vascular Endothelial Growth Factor-2 Gene Therapy in Myocardial Ischemia
Circulation,
September 14, 2004;
110(11):
1398 - 1405.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G.M Rubanyi
The design and preclinical testing of Ad5FGF-4 to treat chronic myocardial ischaemia
Eur. Heart J. Suppl.,
September 1, 2004;
6(suppl_E):
E12 - E17.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L.G Melo, M Gnecchi, A.S Pachori, K Wang, and V.J Dzau
Gene- and cell-based therapies for cardiovascular diseases: current status and future directions
Eur. Heart J. Suppl.,
September 1, 2004;
6(suppl_E):
E24 - E35.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
V. van Weel, M. M.L. Deckers, J. M. Grimbergen, K. J.M. van Leuven, J. H.P. Lardenoye, R. O. Schlingemann, G. P. van Nieuw Amerongen, J. H. van Bockel, V. W.M. van Hinsbergh, and P. H.A. Quax
Vascular Endothelial Growth Factor Overexpression in Ischemic Skeletal Muscle Enhances Myoglobin Expression In Vivo
Circ. Res.,
July 9, 2004;
95(1):
58 - 66.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Losordo and S. Dimmeler
Therapeutic Angiogenesis and Vasculogenesis for Ischemic Disease: Part I: Angiogenic Cytokines
Circulation,
June 1, 2004;
109(21):
2487 - 2491.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. G. Melo, A. S. Pachori, D. Kong, M. Gnecchi, K. Wang, R. E. Pratt, and V. J. Dzau
Molecular and Cell-Based Therapies for Protection, Rescue, and Repair of Ischemic Myocardium: Reasons for Cautious Optimism
Circulation,
May 25, 2004;
109(20):
2386 - 2393.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Svorkdal
Treatment of Inoperable Coronary Disease and Refractory Angina: Spinal Stimulators, Epidurals, Gene Therapy, Transmyocardial Laser, and Counterpulsation
Seminars in Cardiothoracic and Vascular Anesthesia,
March 1, 2004;
8(1):
43 - 58.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Kirchmair, R. Gander, M. Egger, A. Hanley, M. Silver, A. Ritsch, T. Murayama, N. Kaneider, W. Sturm, M. Kearny, et al.
The Neuropeptide Secretoneurin Acts as a Direct Angiogenic Cytokine In Vitro and In Vivo
Circulation,
February 17, 2004;
109(6):
777 - 783.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Pels, C. Deiner, S. E Coupland, M. Noutsias, A. P Sutter, H.-P. Schultheiss, S. Yla-Herttuala, and P. L Schwimmbeck
Effect of adventitial VEGF165 gene transfer on vascular thickening after coronary artery balloon injury
Cardiovasc Res,
December 1, 2003;
60(3):
664 - 672.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. P. Fam, S. Verma, M. Kutryk, and D. J. Stewart
Clinician Guide to Angiogenesis
Circulation,
November 25, 2003;
108(21):
2613 - 2618.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A.U. Heilmann, T. Attmann, A. Thiem, E. Haffner, F. Beyersdorf, and G. Lutter
Gene therapy in cardiac surgery: intramyocardial injection of naked plasmid DNA for chronic myocardial ischemia
Eur. J. Cardiothorac. Surg.,
November 1, 2003;
24(5):
785 - 793.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Russell and K.-W. Peng
Primer on Medical Genomics Part X: Gene Therapy
Mayo Clin. Proc.,
November 1, 2003;
78(11):
1370 - 1383.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. M. Bengel, M. Anton, T. Richter, M. V. Simoes, R. Haubner, J. Henke, W. Erhardt, S. Reder, T. Lehner, W. Brandau, et al.
Noninvasive Imaging of Transgene Expression by Use of Positron Emission Tomography in a Pig Model of Myocardial Gene Transfer
Circulation,
October 28, 2003;
108(17):
2127 - 2133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-s. Yoon and D. W. Losordo
All in the Family: VEGF-B Joins the Ranks of Proangiogenic Cytokines
Circ. Res.,
July 25, 2003;
93(2):
87 - 90.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Thompson, B. A. Nasseri, J. Makower, S. Houser, M. McGarry, T. Lamson, I. Pomerantseva, J. Y. Chang, H. K. Gold, J. P. Vacanti, et al.
Percutaneous transvenous cellular cardiomyoplasty: A novel nonsurgical approach for myocardial cell transplantation
J. Am. Coll. Cardiol.,
June 4, 2003;
41(11):
1964 - 1971.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Fuchs, L. F. Satler, R. Kornowski, P. Okubagzi, G. Weisz, R. Baffour, R. Waksman, N. J. Weissman, M. Cerqueira, M. B. Leon, et al.
Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: A feasibility study
J. Am. Coll. Cardiol.,
May 21, 2003;
41(10):
1721 - 1724.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Henry, B. H. Annex, G. R. McKendall, M. A. Azrin, J. J. Lopez, F. J. Giordano, P.K. Shah, J. T. Willerson, R. L. Benza, D. S. Berman, et al.
The VIVA Trial: Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis
Circulation,
March 18, 2003;
107(10):
1359 - 1365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. E. Strauer and R. Kornowski
Stem Cell Therapy in Perspective
Circulation,
February 25, 2003;
107(7):
929 - 934.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Perin, Y.-J. Geng, and J. T. Willerson
Adult Stem Cell Therapy in Perspective
Circulation,
February 25, 2003;
107(7):
935 - 938.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. W. Sellke and M. Ruel
Vascular growth factors and angiogenesis in cardiac surgery
Ann. Thorac. Surg.,
February 1, 2003;
75(2):
S685 - 690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ruel, R. A. Kelly, and F. W. Sellke
Therapeutic Angiogenesis, Transmyocardial Laser Revascularization, and Cell Therapy
Card. Surg. Adult,
January 1, 2003;
2(2003):
715 - 750.
[Full Text]
|
|
|
|
|
|
|
Z. He, C. Rask-Madsen, and G.L. King
Mechanisms of cardiovascular complications in diabetes and potential new pharmacological therapies
Eur. Heart J. Suppl.,
January 1, 2003;
5(suppl_B):
B51 - B57.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. W. Losordo and A. Kawamoto
Biological Revascularization and the Interventional Molecular Cardiologist: Bypass for the Next Generation
Circulation,
December 10, 2002;
106(24):
3002 - 3005.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kamihata, H. Matsubara, T. Nishiue, S. Fujiyama, K. Amano, O. Iba, T. Imada, and T. Iwasaka
Improvement of Collateral Perfusion and Regional Function by Implantation of Peripheral Blood Mononuclear Cells Into Ischemic Hibernating Myocardium
Arterioscler Thromb Vasc Biol,
November 1, 2002;
22(11):
1804 - 1810.
[Abstract]
[Full Text]
[PDF]
|
|
|
Top
Abstract
Introduction
